

Juho J Miettinen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4304682/publications.pdf>

Version: 2024-02-01

18
papers

763
citations

1478505

6
h-index

1058476

14
g-index

19
all docs

19
docs citations

19
times ranked

1375
citing authors

#	ARTICLE	IF	CITATIONS
1	Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. <i>Nature Cell Biology</i> , 2008, 10, 527-537.	10.3	406
2	HSV-1 ICP27 targets the TBK1-activated STING signalingosome to inhibit virus-induced type I IFN expression. <i>EMBO Journal</i> , 2016, 35, 1385-1399.	7.8	173
3	Global Secretome Characterization of Herpes Simplex Virus 1-Infected Human Primary Macrophages. <i>Journal of Virology</i> , 2012, 86, 12770-12778.	3.4	45
4	Claudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 pathways and regulates lymphatic vessel development. <i>Genes and Development</i> , 2010, 24, 875-880.	5.9	36
5	Monosodium Urate Activates Src/Pyk2/PI3 Kinase and Cathepsin Dependent Unconventional Protein Secretion From Human Primary Macrophages. <i>Molecular and Cellular Proteomics</i> , 2013, 12, 749-763.	3.8	36
6	Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen. <i>Cancers</i> , 2021, 13, 1527.	3.7	29
7	CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	8
8	Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 4125-4139.	5.2	6
9	Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches. <i>Proteomes</i> , 2021, 9, 42.	3.5	6
10	S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 723016.	3.7	5
11	The Peptide-Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death. <i>HemaSphere</i> , 2022, 6, e687.	2.7	3
12	Abstract 1843: Melflufen efficacy in multiple myeloma with TP53 aberrations. , 2020, , .		2
13	Predictive Response Biomarkers for BET Inhibitors in AML. <i>Blood</i> , 2018, 132, 2749-2749.	1.4	2
14	In Vitro and in Vivo Activity of Melflufen in Amyloidosis. <i>Blood</i> , 2019, 134, 3100-3100.	1.4	2
15	Phosphoproteomic Analysis of Primary Myeloma Patient Samples Identifies Distinct Phosphorylation Signatures Correlating with Chemo-Sensitivity Profiles in an Ex Vivo Drug Sensitivity Testing Platform. <i>Blood</i> , 2021, 138, 2666-2666.	1.4	2
16	Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen. <i>Cells</i> , 2022, 11, 1574.	4.1	2
17	Single Cell RNA Sequencing Identifies Potential Molecular Indicators of Response to Melflufen in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1194-1194.	1.4	0
18	Integration of Deep Multi-Omics Profiling Veals New Insights into the Biology of Poor-Risk Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 39-40.	1.4	0